Frederick Frank
Vice Chairman
Peter J. Solomon Company

← Back

Frederick Frank is vice chairman of Peter J. Solomon Company. Before joining Peter J. Solomon Company, Mr. Frank was vice chairman of Lehman Brothers and Barclays Capital. Before joining Lehman Brothers as a partner in October 1969, Mr. Frank was co-director of research, as well as vice president and director, of Smith, Barney & Co. Incorporated. He is a chartered financial analyst, a member of the New York Society of Security Analysts, and a past president of the Chemical Processing Industry Analysts.

Born in Salt Lake City on May 31, 1932, Mr. Frank graduated from the Hotchkiss School in 1950 and from Yale University in 1954. He then spent two years in the Army, most of the time stationed with Supreme Headquarters Allied Powers Europe (SHAPE) in Paris. After release from service, he attended Stanford Graduate School of Business Administration. He received his MBA from Stanford in 1958 and began his Wall Street career that year. He also has a CFA degree.

Mr. Frank is a director of Landec Corporation; PDL BioPharma, Institute for Systems Biology; and Pharmaceutical Product Development, Inc. He is chairman of the National Genetics Foundation; a past director of the Salk Institute; a member of the Yale School of Management advisory board, a member of the advisory boards for Pharmaceutical Executive magazine and the Journal of Life Sciences, the former chairman of the board of the Irvington Institute for Immunological Research, a member of the advisory board of the Harvard School of Public Health, and a past member of the advisory board of the John’s Hopkins Bloomberg School of Public Health, and he serves on the advisory boards of the Massachusetts Institute of Technology Center for Biomedical Innovation and Burrill and Co. He is past president of the board of the the Hotchkiss School, and currently serves as a trustee emeritus.

Mr. Frank was honored for Outstanding Contributions in the Field of Immunology in 1998 by the Irvington Institute for Immunological Research, and, in 1997, he received the Biotech Meeting at Laguna Niguel Hall of Fame Award for Special Recognition for an Individual. He received the Albert Einstein Award from the Weizmann Institute of Science in 2004 and the 2006 Gilda’s Club of New York City Visionary Award, was selected for the Top 100 Living Contributors to Biotechnology by Reed Elsevier, and in 2007 received the Award for Excellence from the American Liver Foundation.

Mr. Frank has provided investment banking services to an extensive number of companies in the pharmaceutical, biotechnology, healthcare service provider, medical device, and nutraceutical industries, and has been involved in hundreds of financings and merger and acquisition transactions in the global healthcare industry.